USA flag logo/image

An Official Website of the United States Government

STAT Palm-Sized Blood Counter

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96318
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL099092
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
DNA MEDICINE INSTITUTE
727 Massachusetts Avenue Cambridge, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: STAT Palm-Sized Blood Counter
Agency: HHS
Contract: 1R43HL099092-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this proposal is to develop a STAT palm-sized blood counter for monitoring complete blood counts (CBC) during emergencies. Changes in blood counts can reflect acutely worsening medical conditions. For instan ce, a rapidly rising white blood cell count may occur during infections or leukemic blast crises. Hematocrit values may rapidly decline in traumas, gastrointestinal bleeds, and post-procedure recoveries. Platelet values may drop significantly during chemot herapy and idiopathic thrombocytopenic purpura. During these situations, close and frequent monitoring of a patient's CBC is a must to deliver the best care and treatment, whether it be blood transfusions, platelet transfusions, or drug administrations. Th e proposed blood counter samples a fingerstick of blood from the patient and analyzes it in real-time at the patient's side for point-of-emergency clinical decision making. This is in contrast to today's CBC measurement technologies, which require a bencht op instrument and a trained technician. The central hypothesis for this Phase I-III SBIR effort is this: microfluidic technology can be utilized to develop an integrated palm-sized blood counter that requires only a pinprick of blood. The proposed 12-month 100,000 Phase I research is based on work at the DNA Medicine Institute that includes developments in flow-focusing, detection, micromixing, and integration. For each of these areas, we have conceived or discovered novel approaches that can potentially a ugment accuracy, increase integration, and diminish the size of our blood counter. These miniaturized advances will be explored in our Specific Aims. Specific Aim 1 will identify the optimal flow-focusing and detection format for measurement of cell counts and volume. Specific Aim 2 will characterize prototype low Reynolds number micromixers with respect to mixing efficiency, functional Re, and blood compatibility. Specific Aim 3 will assess the performance of our prototype integrated microfluidic blood cou nter in measuring hematocrits relative to a predicate method. Successful completion of Phase I will support our core hypothesis and lead to a Phase II effort that will be utilized for developing a palm-sized prototype that is capable of bringing full hemat ology capabilities, a complete CBC and 5-part differential, to point-of-emergency situations. Phase III will comprise of development, FDA approvals, and commercialization. The resulting product would be applicable for emergencies in a wide-range of setting s including ambulances, inpatient rooms, operating rooms, medical offices, and resource-starved settings. PUBLIC HEALTH RELEVANCE: NARRATIVE This research is relevant to public health because rapid diagnosis of blood counts can be the difference bet ween life and death. The palm-sized blood counter product is designed to provide much needed medical information during critical emergencies.

Principal Investigator:

Eugene Y. Chan
6172337656
ECHAN@DNAMEDINSTITUTE.COM

Business Contact:

Eugene Y. Chan
echan@dnamedinstitute.com
Small Business Information at Submission:

DNA MEDICINE INSTITUTE
727 Massachusetts Avenue Cambridge, MA 02139

EIN/Tax ID: 120209884
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No